Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Salomon & Ludwin LLC

Salomon & Ludwin LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 35.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 927 shares of the medical research company's stock after selling 519 shares during the period. Salomon & Ludwin LLC's holdings in Thermo Fisher Scientific were worth $482,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Roxbury Financial LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $153,000. Guyasuta Investment Advisors Inc. increased its position in shares of Thermo Fisher Scientific by 1.8% in the fourth quarter. Guyasuta Investment Advisors Inc. now owns 105,664 shares of the medical research company's stock valued at $54,970,000 after buying an additional 1,821 shares in the last quarter. Aveo Capital Partners LLC lifted its position in shares of Thermo Fisher Scientific by 33.4% during the 4th quarter. Aveo Capital Partners LLC now owns 1,231 shares of the medical research company's stock valued at $640,000 after buying an additional 308 shares in the last quarter. Accretive Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 381.7% in the 4th quarter. Accretive Wealth Partners LLC now owns 2,876 shares of the medical research company's stock valued at $1,496,000 after acquiring an additional 2,279 shares during the period. Finally, WealthPlan Investment Management LLC raised its position in Thermo Fisher Scientific by 6.1% during the fourth quarter. WealthPlan Investment Management LLC now owns 4,211 shares of the medical research company's stock worth $2,190,000 after acquiring an additional 241 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Activity

In related news, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares of the company's stock, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now owns 111,192 shares in the company, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,125 shares of company stock valued at $11,231,699 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Up 1.6 %

NYSE TMO traded up $8.32 during trading on Wednesday, reaching $531.41. 1,965,169 shares of the company's stock were exchanged, compared to its average volume of 2,104,480. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The stock has a market cap of $203.26 billion, a P/E ratio of 32.15, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a 50 day moving average price of $548.10 and a two-hundred day moving average price of $568.36.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board of directors believes its stock is undervalued.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.44%.

Analysts Set New Price Targets

TMO has been the subject of several research reports. Wells Fargo & Company boosted their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Raymond James restated an "outperform" rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, Citigroup upped their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a "neutral" rating in a research report on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $658.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.